Indian pharmaceutical major Cipla has initiated a recall of a cancer treatment drug in the United States after regulatory authorities identified manufacturing-related concerns. According to information released by the U.S. Food and Drug Administration, the recall was issued as part of routine quality surveillance designed to ensure the safety and efficacy of medicines distributed in the American market. While the recall does not necessarily indicate widespread harm to patients, it highlights the stringent compliance standards required for pharmaceutical companies operating globally.
